Opis

• Tytuł:
  Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®)
• Twórca:
  Muciek, Adrianna;
  Mocarska, Martyna;
  Orłowska, Anna;
  Strakowska, Katarzyna;
  Opalska, Laura;
  Maryńczak, Anna;
  Mencel, Jan;
  Nitschke, Nicole
• Opis:
  Alzheimer's disease represents one of the most significant challenges in the field of neurology, affecting millions of individuals worldwide. In pursuing efficacious treatments, lecanemab has emerged as a promising therapeutic option. This pioneering monoclonal antibody targets and reduces amyloid-beta plaques in the brain, a defining feature of Alzheimer's disease. By addressing one of the fundamental causes of the disease, lecanemab represents a novel approach to slowing its progression.  On 14th November 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting marketing authorisation for Leqembi® (whose active substance is lecanemab). This recommendation is specifically directed towards patients with early-onset Alzheimer's disease who are non-carriers or heterozygotes for the apolipoprotein E ε4 (ApoE ε4) allele, thereby underscoring the drug's efficacy tailored to specific genetic profiles (Committee for Medicinal Products for Human Use, 2024). The CHMP's approval is a testament to the extensive research and clinical trials that have demonstrated the efficacy and safety of Leqembi® (Lecanemab). This narrative review aims to provide a comprehensive examination of these aspects and offer a detailed understanding of the potential impact of this treatment on the management of early Alzheimer's disease. 
• Dostępność obiektu:
  Dostęp otwarty
• Prawa: https://creativecommons.org/licenses/by-nc-sa/4.0 ;
  Prawa autorskie (c) 2024 Adrianna Muciek, Martyna Mocarska, Anna Orłowska, Katarzyna Strakowska, Laura Opalska, Anna Maryńczak, Jan Mencel, Nicole Nitschke
• Data:
  2024.12.27
• Typ:
  info:eu-repo/semantics/article;
  info:eu-repo/semantics/publishedVersion
• Język:
  angielski
• Źródło:
  Quality in Sport; Tom 25 (2024); 56711;
  Quality in Sport; Vol. 25 (2024); 56711;
  2450-3118
• Format:
  application/pdf
• Wydawca:
  University Center for Sports Research, Nicolaus Copernicus University, Torun, Poland
• Relacja: https://apcz.umk.pl/QS/article/view/56711/40881
• Temat i słowa kluczowe:
  Leqembi;
  Lecanemab;
  Alzheimer's disease;
  BAN2401
• Identyfikator: https://apcz.umk.pl/QS/article/view/56711
• Dostawca danych:
  Akademicka Platforma Czasopism
• Czy mogę z tego obiektu skorzystać?:
  poproś o pozwolenie
• Rodzaj zawartości:
  teksty